These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
101 related articles for article (PubMed ID: 1997189)
1. Protective and restorative role of AS101 in combination with chemotherapy. Kalechman Y; Albeck M; Oron M; Sobelman D; Gurwith M; Horwith G; Kirsch T; Maida B; Sehgal SN; Sredni B Cancer Res; 1991 Mar; 51(5):1499-503. PubMed ID: 1997189 [TBL] [Abstract][Full Text] [Related]
2. Protection of bone marrow stromal cells from the toxic effects of cyclophosphamide in vivo and of ASTA-Z 7557 and etoposide in vitro by ammonium trichloro(dioxyethylene-O-O')tellurate (AS101). Kalechman Y; Sotnik-Barkai I; Albeck M; Sredni B Cancer Res; 1993 Apr; 53(8):1838-44. PubMed ID: 8467503 [TBL] [Abstract][Full Text] [Related]
3. Effect of the immunomodulator AS101 on chemotherapy-induced multilineage myelosuppression, thrombocytopenia, and anemia in mice. Kalechman Y; Rushkin G; Nerubay J; Albeck M; Sredni B Exp Hematol; 1995 Dec; 23(13):1358-66. PubMed ID: 7498364 [TBL] [Abstract][Full Text] [Related]
4. In vivo synergistic effect of the immunomodulator AS101 and the PKC inducer bryostatin. Kalechman Y; Albeck M; Sredni B Cell Immunol; 1992 Aug; 143(1):143-53. PubMed ID: 1623562 [TBL] [Abstract][Full Text] [Related]
5. The protective role of ammonium trichloro(dioxoethylene-O,O')tellurate in combination with several cytotoxic drugs acting by different mechanisms of action. Kalechman Y; Shani A; Sotnik-Barkai I; Albeck M; Sredni B Cancer Res; 1993 Dec; 53(24):5962-9. PubMed ID: 8261410 [TBL] [Abstract][Full Text] [Related]
6. Radioprotective effects of the immunomodulator AS101. Kalechman Y; Albeck M; Oron M; Sobelman D; Gurwith M; Seghal SN; Sredni B J Immunol; 1990 Sep; 145(5):1512-7. PubMed ID: 2384668 [TBL] [Abstract][Full Text] [Related]
7. Role of endogenous cytokines secretion in radioprotection conferred by the immunomodulator ammonium trichloro(dioxyethylene-0-0')tellurate. Kalechman Y; Zuloff A; Albeck M; Strassmann G; Sredni B Blood; 1995 Mar; 85(6):1555-61. PubMed ID: 7888674 [TBL] [Abstract][Full Text] [Related]
9. Bone marrow-sparing and prevention of alopecia by AS101 in non-small-cell lung cancer patients treated with carboplatin and etoposide. Sredni B; Albeck M; Tichler T; Shani A; Shapira J; Bruderman I; Catane R; Kaufman B; Kalechman Y J Clin Oncol; 1995 Sep; 13(9):2342-53. PubMed ID: 7666093 [TBL] [Abstract][Full Text] [Related]
10. The immunomodulator AS101 administered orally as a chemoprotective and radioprotective agent. Sredni B; Albeck M; Kazimirsky G; Shalit F Int J Immunopharmacol; 1992 May; 14(4):613-9. PubMed ID: 1521929 [TBL] [Abstract][Full Text] [Related]
11. Use and mechanism of action of AS101 in protecting bone marrow colony forming units-granulocyte-macrophage following purging with ASTA-Z 7557. Kalechman Y; Barkai IS; Albeck M; Horwith G; Sehagl SN; Sredni B Cancer Res; 1991 Oct; 51(20):5614-20. PubMed ID: 1913679 [TBL] [Abstract][Full Text] [Related]
12. The effect of AS101 on the reconstitution of T-cell reactivity following irradiation or cyclophosphamide treatment. Kalechman Y; Sotnik-Barkai I; Albeck M; Sredni B Exp Hematol; 1992 Dec; 20(11):1302-8. PubMed ID: 1493859 [TBL] [Abstract][Full Text] [Related]
13. Induction of acute phase proteins in mice and humans by treatment with AS101, an immunomodulator with radioprotective properties. Kalechman Y; Shani A; Albeck M; Sredni B Immunopharmacology; 1995 Mar; 29(2):149-58. PubMed ID: 7539780 [TBL] [Abstract][Full Text] [Related]
14. Mechanism of radioprotection conferred by the immunomodulator AS101. Kalechman Y; Gafter U; Barkai IS; Albeck M; Sredni B Exp Hematol; 1993 Jan; 21(1):150-5. PubMed ID: 8417951 [TBL] [Abstract][Full Text] [Related]
15. Anti-IL-10 therapeutic strategy using the immunomodulator AS101 in protecting mice from sepsis-induced death: dependence on timing of immunomodulating intervention. Kalechman Y; Gafter U; Gal R; Rushkin G; Yan D; Albeck M; Sredni B J Immunol; 2002 Jul; 169(1):384-92. PubMed ID: 12077268 [TBL] [Abstract][Full Text] [Related]
16. The antitumoral effect of the immunomodulator AS101 and paclitaxel (Taxol) in a murine model of lung adenocarcinoma. Kalechman Y; Shani A; Dovrat S; Whisnant JK; Mettinger K; Albeck M; Sredni B J Immunol; 1996 Feb; 156(3):1101-9. PubMed ID: 8557985 [TBL] [Abstract][Full Text] [Related]
17. Protective effect of the immunomodulator AS101 against cyclophosphamide-induced testicular damage in mice. Carmely A; Meirow D; Peretz A; Albeck M; Bartoov B; Sredni B Hum Reprod; 2009 Jun; 24(6):1322-9. PubMed ID: 19240057 [TBL] [Abstract][Full Text] [Related]
18. The cytoprotective effect of the immunomodulator AS101 against hydrochloride induced gastric lesions. Xu RH; Kalechman Y; Albeck M; Sredni B Res Commun Mol Pathol Pharmacol; 1995 Jan; 87(1):4-20. PubMed ID: 7735728 [TBL] [Abstract][Full Text] [Related]
19. Increased DNA repair ability after irradiation following treatment with the immunomodulator AS101. Kalechman Y; Shani A; Albeck M; Sotnik Barkai I; Sredni B Radiat Res; 1993 Nov; 136(2):197-204. PubMed ID: 8248476 [TBL] [Abstract][Full Text] [Related]
20. Antibabesial effect of the immunomodulator AS101 in mice: role of increased production of nitric oxide. Rosenblatt-Bin H; Klein A; Sredni B Parasite Immunol; 1996 Jun; 18(6):297-306. PubMed ID: 9229382 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]